Profluent Partners with Eli Lilly in $2.25 Billion AI Protein Design Deal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2026
0mins
Source: NASDAQ.COM
- Significant Partnership Value: Profluent's partnership with Eli Lilly is valued at up to $2.25 billion, which includes an upfront payment, potential development and commercial milestone payments, and tiered royalties on net sales, indicating strong mutual commitment to the collaboration.
- Technological Synergy: The collaboration aims to develop more precise and scalable DNA-editing tools by integrating Profluent's AI protein design models with Lilly's expertise in genetic medicines, thereby advancing the field of gene therapy.
- Exclusive Rights Allocation: Profluent will design recombinases for specific genetic targets, while Lilly will hold exclusive rights to develop and commercialize selected candidates, facilitating a faster path to market for innovative therapies.
- Market Potential: As the gene therapy market rapidly evolves, this partnership not only provides Profluent with substantial funding but also enhances its competitive edge in the biopharmaceutical sector through Lilly's established market channels and expertise.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1125.270
Low
950.00
Averages
1192
High
1500
Current: 1125.270
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Path to $1,200 Share Price by 2026
- Market Share Growth: Eli Lilly has captured approximately 60% of the U.S. GLP-1 market, significantly enhancing its competitive position in the rapidly growing obesity and diabetes drug sector, especially against Novo Nordisk's early lead.
- International Market Expansion: In Q1 2026, Lilly's revenue outside the U.S. surged 81% year-over-year to $7.7 billion, indicating the rapid unlocking of international market potential, particularly with rising demand in countries like Germany and France.
- Optimistic Revenue Forecast: With Mounjaro and Zepbound generating nearly $13 billion in Q1 2026, if this growth trend continues, quarterly revenue could reach $16 billion to $17.5 billion by late 2026, positioning annual revenue targets between $60 billion and $70 billion.
- Competitive Risks Persist: While Lilly dominates the GLP-1 market, challenges from Novo Nordisk and the development of new oral obesity therapies could impact its market share and future growth prospects.
See More
Eli Lilly Reports Positive Phase 3 Results for Retatrutide
- Significant Weight Loss: In the TRIUMPH-1 trial, participants receiving 12 mg of retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, indicating the drug's potential to transform obesity treatment and market dynamics.
- Improvement in Related Conditions: Retatrutide not only facilitated weight loss but also reduced knee osteoarthritis pain by 4.3 points (73.1%) and the severity of moderate-to-severe obstructive sleep apnea by 36.1 events/hour (60.6%), demonstrating its efficacy across multiple obesity-related conditions.
- Diabetes Management Breakthrough: In the TRANSCEND-T2D-1 trial, retatrutide achieved A1C reductions of up to 2.0% and an average weight loss of 36.6 lbs (16.8%) at 40 weeks, highlighting its significant role in diabetes management and potential market impact.
- Cardiovascular Risk Reduction: In TRIUMPH-1, retatrutide significantly lowered triglycerides by 41%, non-HDL cholesterol by 24.2%, and systolic blood pressure by 12.3 mmHg, suggesting its potential to improve cardiovascular health and broaden market opportunities for the company.
See More
Eli Lilly Reports Positive Results for Obesity Drug Retatrutide
- Significant Weight Loss: In the Phase 3 TRIUMPH-1 study, adults receiving the highest dose of retatrutide lost an average of 70.3 pounds (31.89 kg), or 28.3% of their body weight, demonstrating the drug's strong potential in the weight loss sector and positioning it as a potential blockbuster for Lilly in the obesity treatment market.
- Health Condition Improvements: The study revealed that retatrutide reduced breathing interruptions by up to 36.1 events per hour in patients with moderate-to-severe obstructive sleep apnea, representing a 61% improvement, while pain scores in knee osteoarthritis patients decreased by 73%, indicating the drug's effectiveness in addressing obesity-related health issues.
- Diabetes Control Effectiveness: In the TRANSCEND-T2D-1 study, retatrutide lowered A1C levels by up to 2 percentage points in type 2 diabetes patients, with 90% achieving an A1C below 7%, showcasing the drug's potential in diabetes management and its broader implications for patient health.
- Cardiovascular Risk Improvements: Across both studies, retatrutide improved several heart disease risk factors, including reductions in triglycerides and non-HDL cholesterol, along with lower blood pressure and waist circumference, enhancing the drug's market appeal and potential for widespread adoption.
See More
Eli Lilly Acquires Vaccine Firms to Diversify Business
- Significant Revenue Growth: Eli Lilly reported $12.8 billion in revenue for Q1 2026, with Mounjaro and Zepbound accounting for nearly two-thirds, showcasing strong market demand and the company's leadership in the GLP-1 weight-loss drug category with year-over-year sales growth of 125% and 80%, respectively.
- Strategic Acquisition Moves: The company is spending $3.8 billion to acquire Curevo, LimmaTech Biologics AG, and Vaccine Company, rapidly enhancing its presence in the infectious disease sector, which, while having limited short-term impact, lays the groundwork for future market expansion.
- Forward-Looking Business Planning: Eli Lilly recognizes that the success of its GLP-1 drugs is not everlasting, thus this acquisition is a proactive measure to ensure competitiveness after patent protections expire, preparing for sustained growth in the long term.
- Industry Leadership Focus: Despite a high P/E ratio of 39, significantly above the pharmaceutical average of 24, Eli Lilly's management is committed to diversifying its portfolio and developing new GLP-1 drugs, aiming to solidify its leadership position and achieve long-term success in the pharmaceutical industry.
See More
Eli Lilly's $3.8 Billion Vaccine Investment
- Vaccine Investment Strategy: Eli Lilly's recent $3.8 billion acquisition of Curevo, LimmaTech Biologics AG, and Vaccine Company rapidly enhances its presence in the infectious disease sector, which, while having limited short-term impact, lays the groundwork for future growth.
- GLP-1 Drug Performance: The GLP-1 weight-loss drugs Mounjaro and Zepbound achieved sales growth of 125% and 80% respectively in Q1 2026, collectively generating approximately $12.8 billion in revenue, demonstrating strong market demand and leadership position.
- Diversification Strategy: Recognizing that the success of GLP-1 drugs is not everlasting, Eli Lilly is strategically investing in vaccines to mitigate risks and ensure sustained business growth in the future, reflecting sound financial stewardship.
- Investor Focus: While value investors may be cautious about Eli Lilly's high P/E ratio of 39x, growth-oriented investors are likely to be attracted by the potential of its GLP-1 drugs and new drug developments, indicating the company's long-term growth potential in the pharmaceutical industry.
See More
Eli Lilly Reports Positive Phase 3 Results for Weight Loss Drug Retatrutide
- Significant Weight Loss: In the 80-week TRIUMPH-1 trial, participants taking a 12 mg dose of retatrutide lost an average of 70.3 pounds, achieving a 28.3% reduction in body weight, with 65.3% of patients reaching a BMI below 30, thus no longer meeting clinical obesity criteria.
- Improvement in Related Conditions: The trial demonstrated that retatrutide significantly reduced knee osteoarthritis pain by up to 73.1% for patients with joint complications, while also lowering the severity of moderate-to-severe obstructive sleep apnea by 60.6%, highlighting its potential in improving overall health.
- Diabetes Management Efficacy: In the 40-week TRANSCEND-T2D-1 trial, patients achieved an average blood sugar reduction of 2.0%, with nearly half reaching normal glycemic levels alongside a 16.8% reduction in body weight, indicating the drug's effectiveness in managing diabetes.
- Cardiovascular Health Improvement: Retatrutide also showed efficacy in cardiovascular health, lowering triglycerides by up to 41.0% and systolic blood pressure by 12.3 mmHg, although there was an 11.3% discontinuation rate at the highest dosage primarily due to gastrointestinal side effects.
See More
Eli Lilly's Path to $1,200 Share Price by 2026
- Market Share Growth: Eli Lilly has captured approximately 60% of the U.S. GLP-1 market, significantly enhancing its competitive position in the rapidly growing obesity and diabetes drug sector, especially against Novo Nordisk's early lead.
- International Market Expansion: In Q1 2026, Lilly's revenue outside the U.S. surged 81% year-over-year to $7.7 billion, indicating the rapid unlocking of international market potential, particularly with rising demand in countries like Germany and France.
- Optimistic Revenue Forecast: With Mounjaro and Zepbound generating nearly $13 billion in Q1 2026, if this growth trend continues, quarterly revenue could reach $16 billion to $17.5 billion by late 2026, positioning annual revenue targets between $60 billion and $70 billion.
- Competitive Risks Persist: While Lilly dominates the GLP-1 market, challenges from Novo Nordisk and the development of new oral obesity therapies could impact its market share and future growth prospects.
See More
Eli Lilly Reports Positive Phase 3 Results for Retatrutide
- Significant Weight Loss: In the TRIUMPH-1 trial, participants receiving 12 mg of retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, indicating the drug's potential to transform obesity treatment and market dynamics.
- Improvement in Related Conditions: Retatrutide not only facilitated weight loss but also reduced knee osteoarthritis pain by 4.3 points (73.1%) and the severity of moderate-to-severe obstructive sleep apnea by 36.1 events/hour (60.6%), demonstrating its efficacy across multiple obesity-related conditions.
- Diabetes Management Breakthrough: In the TRANSCEND-T2D-1 trial, retatrutide achieved A1C reductions of up to 2.0% and an average weight loss of 36.6 lbs (16.8%) at 40 weeks, highlighting its significant role in diabetes management and potential market impact.
- Cardiovascular Risk Reduction: In TRIUMPH-1, retatrutide significantly lowered triglycerides by 41%, non-HDL cholesterol by 24.2%, and systolic blood pressure by 12.3 mmHg, suggesting its potential to improve cardiovascular health and broaden market opportunities for the company.
See More
Eli Lilly Reports Positive Results for Obesity Drug Retatrutide
- Significant Weight Loss: In the Phase 3 TRIUMPH-1 study, adults receiving the highest dose of retatrutide lost an average of 70.3 pounds (31.89 kg), or 28.3% of their body weight, demonstrating the drug's strong potential in the weight loss sector and positioning it as a potential blockbuster for Lilly in the obesity treatment market.
- Health Condition Improvements: The study revealed that retatrutide reduced breathing interruptions by up to 36.1 events per hour in patients with moderate-to-severe obstructive sleep apnea, representing a 61% improvement, while pain scores in knee osteoarthritis patients decreased by 73%, indicating the drug's effectiveness in addressing obesity-related health issues.
- Diabetes Control Effectiveness: In the TRANSCEND-T2D-1 study, retatrutide lowered A1C levels by up to 2 percentage points in type 2 diabetes patients, with 90% achieving an A1C below 7%, showcasing the drug's potential in diabetes management and its broader implications for patient health.
- Cardiovascular Risk Improvements: Across both studies, retatrutide improved several heart disease risk factors, including reductions in triglycerides and non-HDL cholesterol, along with lower blood pressure and waist circumference, enhancing the drug's market appeal and potential for widespread adoption.
See More
Eli Lilly Acquires Vaccine Firms to Diversify Business
- Significant Revenue Growth: Eli Lilly reported $12.8 billion in revenue for Q1 2026, with Mounjaro and Zepbound accounting for nearly two-thirds, showcasing strong market demand and the company's leadership in the GLP-1 weight-loss drug category with year-over-year sales growth of 125% and 80%, respectively.
- Strategic Acquisition Moves: The company is spending $3.8 billion to acquire Curevo, LimmaTech Biologics AG, and Vaccine Company, rapidly enhancing its presence in the infectious disease sector, which, while having limited short-term impact, lays the groundwork for future market expansion.
- Forward-Looking Business Planning: Eli Lilly recognizes that the success of its GLP-1 drugs is not everlasting, thus this acquisition is a proactive measure to ensure competitiveness after patent protections expire, preparing for sustained growth in the long term.
- Industry Leadership Focus: Despite a high P/E ratio of 39, significantly above the pharmaceutical average of 24, Eli Lilly's management is committed to diversifying its portfolio and developing new GLP-1 drugs, aiming to solidify its leadership position and achieve long-term success in the pharmaceutical industry.
See More
Eli Lilly's $3.8 Billion Vaccine Investment
- Vaccine Investment Strategy: Eli Lilly's recent $3.8 billion acquisition of Curevo, LimmaTech Biologics AG, and Vaccine Company rapidly enhances its presence in the infectious disease sector, which, while having limited short-term impact, lays the groundwork for future growth.
- GLP-1 Drug Performance: The GLP-1 weight-loss drugs Mounjaro and Zepbound achieved sales growth of 125% and 80% respectively in Q1 2026, collectively generating approximately $12.8 billion in revenue, demonstrating strong market demand and leadership position.
- Diversification Strategy: Recognizing that the success of GLP-1 drugs is not everlasting, Eli Lilly is strategically investing in vaccines to mitigate risks and ensure sustained business growth in the future, reflecting sound financial stewardship.
- Investor Focus: While value investors may be cautious about Eli Lilly's high P/E ratio of 39x, growth-oriented investors are likely to be attracted by the potential of its GLP-1 drugs and new drug developments, indicating the company's long-term growth potential in the pharmaceutical industry.
See More
Eli Lilly Reports Positive Phase 3 Results for Weight Loss Drug Retatrutide
- Significant Weight Loss: In the 80-week TRIUMPH-1 trial, participants taking a 12 mg dose of retatrutide lost an average of 70.3 pounds, achieving a 28.3% reduction in body weight, with 65.3% of patients reaching a BMI below 30, thus no longer meeting clinical obesity criteria.
- Improvement in Related Conditions: The trial demonstrated that retatrutide significantly reduced knee osteoarthritis pain by up to 73.1% for patients with joint complications, while also lowering the severity of moderate-to-severe obstructive sleep apnea by 60.6%, highlighting its potential in improving overall health.
- Diabetes Management Efficacy: In the 40-week TRANSCEND-T2D-1 trial, patients achieved an average blood sugar reduction of 2.0%, with nearly half reaching normal glycemic levels alongside a 16.8% reduction in body weight, indicating the drug's effectiveness in managing diabetes.
- Cardiovascular Health Improvement: Retatrutide also showed efficacy in cardiovascular health, lowering triglycerides by up to 41.0% and systolic blood pressure by 12.3 mmHg, although there was an 11.3% discontinuation rate at the highest dosage primarily due to gastrointestinal side effects.
See More
